ArticleOphthalmology science2026
Deep Learning Model to Detect Diabetic Retinopathy in 45° Images Using Ground Truth from Ultra-Widefield Imaging.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the performance of a deep learning (DL) model in classifying diabetic retinopathy (DR) severity using fundus images with varying fields of view and to assess whether central retinal features alone reflect overall disease burden. The study also investigates vascular biomarkers within regions contributing to model decisions to explore biological basis of inferences and enhance clinical interpretability. Design: An observational, cross-sectional study. Participants: A total of 2610 participants aged ≥40 years from a population-based study in South India, with ocular and systemic data, including dilated fundus images and glycated hemoglobin levels. Methods: Diabetic retinopathy severity was graded on unmasked 200° ultra-widefield (UWF) and centrally masked 45° images, with peripheral lesions annotated in the 155° field (200°-45°). Convolutional neural network was trained on labeled images and evaluated on both datasets. Performance metrics and receiver operating characteristic (ROC) curves were calculated. Gradient-weighted class activation mapping (Grad-CAM) identified model focus. Vascular biomarkers (tortuosity, fractal dimension, and vessel density) were quantified using LWNet and Fiji software and compared between eyes with and without peripheral lesions. Main Outcome Measures: Classification accuracy of DR severity, precision and recall, ROC curves, Grad-CAM visualization of regions of model focus, and vascular biomarkers associated with peripheral lesions. Results: The DL model achieved high classification accuracy: 97.12% for UWF images, 97.24% for 45° masked images with re-evaluated labels, and 96.86% for masked images with original labels. Peripheral pathology, including microaneurysms (19.8%) and hemorrhages/exudates (9.1%), did not affect accuracy. Deep learning-based assessment of 45° fundus images reduced DR underestimation from 16.5% to 6.2%. Gradient-weighted class activation mapping highlighted focus on central regions, including areas without visible lesions. Vascular analysis revealed differences in vessel density and tortuosity between eyes with and without peripheral microvascular abnormalities and neovascularization, suggesting detection of subclinical vascular changes linked to peripheral disease. Conclusions: Deep learning applied to 45° fundus images can accurately classify DR and detect subtle vascular biomarkers predictive of peripheral disease. This proof-of-concept highlights the potential of artificial intelligence (AI)-enhanced 45° imaging as a scalable tool for DR screening. Such AI-powered approaches, using accessible and affordable fundus cameras, may enable cost-effective detection and triage of high-risk cases in primary care and resource-limited settings. Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.